GPX4 and non-small cell lung carcinoma: In non-small cell lung cancer, NRF2 upregulates GPX4 and superoxide dismutase 2, conferring resistance to epidermal growth factor receptor tyrosine kinase inhibitors[57], which can be overcome by inhibiting GPX4 to induce ferroptosis[58].